Abstract
Macrophage migration inhibitor factor (MIF) is a highly conserved and evolutionarily ancient mediator with pleiotropic effects that has been implicated in tumor growth and progression. MIFs function is unique among cytokines and its effects extend to multiple processes fundamental to tumorigenesis such as tumor proliferation, evasion of apoptosis, angiogenesis and invasion. These pleiotropic functional aspects are paralleled by MIFs unique signaling properties, which involve activation of the ERK-1/2 and AKT pathways and the regulation of JAB1, p53, SCF ubiquitin ligases and HIF-1. These properties reflect features central to growth regulation, apoptosis and cell cycle control than is typical for an immune cytokine. The significance of these pro-tumorigenic properties has found support in several in vitro and in vivo models of cancer and in the positive association between MIF production and tumor aggressiveness and metastatic potential in a variety of human tumors.
Keywords: Macrophage migration inhibitory factor, HIF-1, P53, TAM, angiogenesis, tumor progression, CD44, CD74
Current Pharmaceutical Design
Title: Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Volume: 14 Issue: 36
Author(s): Carlo Bifulco, Katy McDaniel, Lin Leng and Richard Bucala
Affiliation:
Keywords: Macrophage migration inhibitory factor, HIF-1, P53, TAM, angiogenesis, tumor progression, CD44, CD74
Abstract: Macrophage migration inhibitor factor (MIF) is a highly conserved and evolutionarily ancient mediator with pleiotropic effects that has been implicated in tumor growth and progression. MIFs function is unique among cytokines and its effects extend to multiple processes fundamental to tumorigenesis such as tumor proliferation, evasion of apoptosis, angiogenesis and invasion. These pleiotropic functional aspects are paralleled by MIFs unique signaling properties, which involve activation of the ERK-1/2 and AKT pathways and the regulation of JAB1, p53, SCF ubiquitin ligases and HIF-1. These properties reflect features central to growth regulation, apoptosis and cell cycle control than is typical for an immune cytokine. The significance of these pro-tumorigenic properties has found support in several in vitro and in vivo models of cancer and in the positive association between MIF production and tumor aggressiveness and metastatic potential in a variety of human tumors.
Export Options
About this article
Cite this article as:
Bifulco Carlo, McDaniel Katy, Leng Lin and Bucala Richard, Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor, Current Pharmaceutical Design 2008; 14 (36) . https://dx.doi.org/10.2174/138161208786898608
DOI https://dx.doi.org/10.2174/138161208786898608 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
(Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) Mammalian Nucleoside Transporters
Current Drug Metabolism Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets The Role of RNA Modifications and RNA-modifying Proteins in Cancer Therapy and Drug Resistance
Current Cancer Drug Targets Exploring a Novel Target Treatment on Breast Cancer: Aloe-emodin Mediated Photodynamic Therapy Induced Cell Apoptosis and Inhibited Cell Metastasis
Anti-Cancer Agents in Medicinal Chemistry Nano-Enabled Drug Delivery in Cancer Therapy: Literature Analysis Using the MeSH System
Pharmaceutical Nanotechnology Gene Expression Significance in Personalized Medicine of Non-small Cell Lung Cancer and Gene Expression Analyzing Platforms
Current Drug Metabolism Depleted Uranium and Human Health
Current Medicinal Chemistry Current Prospects of Synthetic Curcumin Analogs and Chalcone Derivatives Against Mycobacterium Tuberculosis
Medicinal Chemistry Hepatic Steatosis and Peroxisomal Fatty Acid Beta-oxidation
Current Drug Metabolism Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Adiposity and the Gut - The Role of Gut Hormones
Current Nutrition & Food Science Management of Fallopian Tube Cancer
Reviews on Recent Clinical Trials Association of N-Acetyltransferase-2 Genotypes and Anti-Tuberculosis Induced Liver Injury: First Case-Controlled Study from Iran
Current Drug Safety Animal Mitochondria: Evolution, Function, and Disease
Current Molecular Medicine Photoactivatable Platinum Complexes
Anti-Cancer Agents in Medicinal Chemistry Synthesis of 9-O-3-(1-piperazinyl/morpholinyl/piperidinyl)pentyl-berberines as Potential Antioxidant and Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Process Variables and Design of Experiments in Liposome and Nanoliposome Research
Mini-Reviews in Medicinal Chemistry Disulfiram's Anticancer Activity: Evidence and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenetics, Pharmacogenomics and Epigenetics of Nrf2-regulated Xenobioticmetabolizing Enzymes and Transporters by Dietary Phytochemical and Cancer Chemoprevention
Current Drug Metabolism